title: White light-mediated Cu (II)-5FU interaction augments the chemotherapeutic potential of 5-FU: an in vitro study.
abstract: 5-Fluorouracil (5-FU) is a potent photosensitizer used in colon and rectal cancers. 5-FU on galvanostatic electrolysis or radiation-induced oxidation of aqueous solution yields N(1)-C(5)-linked dimmer hydrate of 5-FU. Copper is presently associated with chromatin; in cancer cells the concentration of copper is very high. It has been shown to be capable of mediating the action of several anticancer drugs through the production of reactive oxygen species (ROS). The objective of the present study is to determine the Cu (II)-mediated anticancer mechanism of 5-FU under photo-illumination as well as 5-FU alone. We have shown that a pro-oxidant action was enhanced when Cu (II) was used with 5-FU as compared to 5-FU alone. This may be due to the inhibition of dimerization of 5-FU when present in combination with Cu (II) under photo-illumination. It was also shown that 5-FU alone as well as in combination with Cu (II) was able to generate oxidative stress in lymphocyte which is inhibited by scavengers of ROS. Moreover, the results of Fourier-transformed infrared spectra lead to the conclusion that the dimerization of 5-FU was inhibited when used in combination with Cu (II). It was due to the interaction of 5-FU with Cu (II). Hence, we propose that during chemoradiotherapy with 5-FU, the endogenous copper is mobilized by 5-FU, leading to the generation of ROS which cause oxidative stress and possibly cancer cell death by apoptosis.
authors: Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, U.P-202002, India.
authors: Sandesh
authors: S
authors: Chibber
authors: Mohd
authors: M
authors: Farhan
authors: Iftekhar
authors: I
authors: Hassan
authors: Imrana
authors: I
authors: Naseem
references: Invest New Drugs. 2000 Nov;18(4):299-313
references: 11081567
references: Free Radic Biol Med. 1994 Jan;16(1):43-8
references: 8299995
references: Eur J Cancer. 1998 Feb;34(3):296-306
references: 9640213
references: J Org Chem. 2001 Apr 6;66(7):2232-9
references: 11281761
references: Recent Results Cancer Res. 1981;76:100-14
references: 6785848
references: J Med Chem. 1992 Jul 10;35(14):2711-2
references: 1635068
references: Cancer Chemother Pharmacol. 1978;1(4):203-8
references: 750108
references: Eur J Cancer. 2004 Sep;40(13):1934-40
references: 15315800
references: Molecules. 2008 Oct 01;13(10):2370-84
references: 18830160
references: Bioorg Med Chem. 2007 Aug 1;15(15):5047-60
references: 17544277
references: Biochem Pharmacol. 1980 Feb 15;29(4):665-8
references: 6768366
references: FEBS Lett. 2005 Jun 6;579(14):3131-5
references: 15919081
references: Cancer Res. 2006 May 15;66(10):5379-86
references: 16707465
references: J Neurooncol. 1993 May;16(2):109-15
references: 8289088
references: J Med Chem. 1978 Aug;21(8):738-41
references: 357721
references: Org Biomol Chem. 2007 Dec 7;5(23):3745-57
references: 18004453
references: Integr Cancer Ther. 2004 Dec;3(4):294-300
references: 15523100
references: Biochem Pharmacol. 2005 Jul 15;70(2):229-41
references: 15941563
references: Free Radic Res. 2008 Aug;42(8):764-72
references: 18661438
references: Front Biosci. 2004 Sep 01;9:2652-62
references: 15358588
references: Exp Cell Res. 1988 Mar;175(1):184-91
references: 3345800
references: Free Radic Biol Med. 1988;4(4):219-23
references: 2834274
references: Free Radic Biol Med. 2006 Dec 15;41(12):1807-16
references: 17157183